Accession Number: | 0001209191-20-043008 |
Date: | 2020-07-15 |
Issuer: | PRINCIPIA BIOPHARMA INC. (PRNB) |
Original Submission Date: |
THOMAS DOLCA
C/O PRINCIPIA BIOPHARMA INC.
220 E. GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-07-15 | M | 15,000 | a | $23.77 | 16,826 | direct | ||
COMMON STOCK | 2020-07-15 | S | 15,000 | d | $80.07 | 1,826 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 23.77 | 2020-07-15 | deemed execution date | M | 15,000 (d) | 2028-10-22 | common stock 15,000 | $23.77 | 183,057 | direct |
ID | footnote |
---|---|
f1 | includes 1,332 shares shares acquired under the employment stock purchase plan on may 15, 2020. |
f2 | the sales reported on this form 4 were effected pursuant to a rule 10b5-1 trading plan. |
f3 | represents the weighted average sales price per share. the shares sold at prices ranging from $80.00 to $80.28 per share. upon request by the commission staff, issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this form 4. |
f4 | the stock option vested and became exercisable as to 25% of the shares subject to the option on october 22, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the reporting person on each vesting date. |